Every move you make: Biopharma industry under heavy scrutiny
BioSpace · BioSpace
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; meanwhile Sanofi throws in towel over threat of injunction
Renewed interest in psychedelics after MindMed’s Phase IIb trial of its LSD-based candidate meets primary endpoint in patients with generalized anxiety disorder.
Bluebird bio changes its tune, signing an ‘outcomes- based’ agreement with commercial payer, and Pfizer struggles continue.
BioSpace's Lori Ellis, Greg Slabdodkin and Tyler Patchen discuss.
And that's a wrap on 2023! We'll see you in the New Year.